Quick Answer
NOVAVAX INC reported Net Income Loss of $440.30 million for the year ending 2025.
- NOVAVAX INC showed an increase of +334.8% in Net Income Loss from 2024 to 2025.
- This data is from NOVAVAX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), NOVAVAX INC's Net Income Loss has grown by 1,191.3%.
- Historical annual values: Fiscal year 2025: $440.30 million | Fiscal year 2024: -$187.50 million | Fiscal year 2023: -$545.06 million | Fiscal year 2022: -$657.94 million | Fiscal year 2021: -$1.74 billion | Fiscal year 2020: -$418.26 million | Fiscal year 2019: -$132.69 million | Fiscal year 2018: -$184.75 million | Fiscal year 2017: -$183.77 million | Fiscal year 2016: -$279.97 million | Fiscal year 2015: -$156.94 million | Fiscal year 2014: -$82.95 million | Fiscal year 2013: -$51.98 million | Fiscal year 2012: -$28.51 million | Fiscal year 2011: -$19.36 million | Fiscal year 2010: -$35.71 million | Fiscal year 2009: -$40.35 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: